Compare Align Technology, Inc. (ALGN) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs DexCom, Inc. — how do they compare? Align Technology, Inc. trades at $173.38 (market cap $12.29B), while DexCom, Inc. trades at $88.22 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 2.7× Align Technology, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | DXCM | |
|---|---|---|
Market Cap | $12.29B | $33.79B |
Sector | Health | Health |
52-Week High | $197.51 | $89.53 |
52-Week Low | $124.88 | $54.84 |
Enterprise Value | $11.30B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $173.4, down 1.5% today, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, a P/E of 30.03, and a net income margin of 9.99%. Recent news highlights a patent win in China and strategic initiatives under activist investor engagement, supporting its digital orthodontics leadership.
Outlook remains positive due to solid profitability and growth initiatives, but risks include competitive pressures and scanner segment weakness. Analyst consensus is strongly bullish with 73% buy ratings, viewing current valuation as attractive for long-term growth despite near-term technical headwinds.
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
